Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation

Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The “introduction” of MAPPs is already seen by the European Medicines Agency (EMA) as a fait accompli, with payers not consulted or involved. However, onc...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Pharmacol
Asıl Yazarlar: Vella Bonanno, Patricia, Ermisch, Michael, Godman, Brian, Martin, Antony P., Van Den Bergh, Jesper, Bezmelnitsyna, Liudmila, Bucsics, Anna, Arickx, Francis, Bybau, Alexander, Bochenek, Tomasz, van de Casteele, Marc, Diogene, Eduardo, Eriksson, Irene, Fürst, Jurij, Gad, Mohamed, Greičiūtė-Kuprijanov, Ieva, van der Graaff, Martin, Gulbinovic, Jolanta, Jones, Jan, Joppi, Roberta, Kalaba, Marija, Laius, Ott, Langner, Irene, Mardare, Ileana, Markovic-Pekovic, Vanda, Magnusson, Einar, Melien, Oyvind, Meshkov, Dmitry O., Petrova, Guenka I., Selke, Gisbert, Sermet, Catherine, Simoens, Steven, Schuurman, Ad, Ramos, Ricardo, Rodrigues, Jorge, Zara, Corinne, Zebedin-Brandl, Eva, Haycox, Alan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2017
Konular:
Pharmacology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5572364/
https://ncbi.nlm.nih.gov/pubmed/28878667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00497
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller